Dr. West Explains the Pemetrexed Clinical Trial

H. Jack West, MD
Published: Friday, Jul 22, 2011



H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.


H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x